Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Dusseldorf - Delayed Quote EUR

Ascletis Pharma Inc (2VJ.DU)

Compare
0.7700
+0.0350
+(4.76%)
As of 8:10:17 AM GMT+1. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 2VJ.DU

Recent News: 2VJ.DU

View More
Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30

Ascletis Announces Positive Interim Results from First Two Cohorts of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30
PR Newswire 7 days ago
Ascletis Pharma’s ASC30 oral tablet shows promise in obesity trial

Ascletis Pharma’s ASC30 oral tablet shows promise in obesity trial
Clinical Trials Arena last month
Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update

Ascletis Announces Positive Results from U.S. Phase Ia Single Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Provides Program Update
PR Newswire last month
Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model
PR Newswire 2 months ago
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
PR Newswire 3 months ago
Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity

Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity
PR Newswire 3 months ago
Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity

Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity
PR Newswire 5 months ago
Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024

Gannex Announces Poster Presentation of Positive Interim 12-Week Results from Phase II Clinical Trial of ASC41 in Patients with Biopsy-Confirmed MASH at EASL CONGRESS 2024
PR Newswire 8 months ago
Ascletis Announces Strategic Decisions on FXR agonist ASC42

Ascletis Announces Strategic Decisions on FXR agonist ASC42
PR Newswire 10 months ago
Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting

Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
PR Newswire 11 months ago
View More

Related Tickers

KK3A.DU Cytokinetics Inc
44.80
+1.82%
 
1VT.BE Viking Therapeutics Inc
27.46
+0.70%
 
EWTX Edgewise Therapeutics, Inc.
25.77
+2.75%
 
ATNM Actinium Pharmaceuticals, Inc.
1.1500
0.00%
 
BMEA Biomea Fusion, Inc.
2.9599
+4.22%
 
AKRO Akero Therapeutics, Inc.
48.89
+2.98%
 
CYTK Cytokinetics, Incorporated
47.53
+1.89%
 
ALT Altimmune, Inc.
6.02
+1.78%